Quantbot Technologies LP Acquires Shares of 54,441 DaVita Inc. (NYSE:DVA)

Quantbot Technologies LP bought a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 54,441 shares of the company's stock, valued at approximately $8,925,000. Quantbot Technologies LP owned about 0.07% of DaVita at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. FMR LLC raised its position in shares of DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company's stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Bank of Montreal Can raised its holdings in DaVita by 0.9% in the 3rd quarter. Bank of Montreal Can now owns 60,929 shares of the company's stock worth $9,936,000 after acquiring an additional 520 shares during the period. Harvest Fund Management Co. Ltd lifted its position in DaVita by 14.4% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 11,142 shares of the company's stock worth $1,826,000 after acquiring an additional 1,399 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in DaVita by 6.0% during the third quarter. Daiwa Securities Group Inc. now owns 6,187 shares of the company's stock valued at $1,014,000 after acquiring an additional 348 shares during the period. Finally, Summit Trail Advisors LLC grew its position in shares of DaVita by 1.3% in the third quarter. Summit Trail Advisors LLC now owns 23,309 shares of the company's stock valued at $3,821,000 after purchasing an additional 294 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Price Performance

DVA stock traded up $0.97 during trading on Tuesday, hitting $167.96. The company had a trading volume of 517,771 shares, compared to its average volume of 824,427. The company has a fifty day moving average price of $158.34 and a two-hundred day moving average price of $148.65. DaVita Inc. has a fifty-two week low of $98.26 and a fifty-two week high of $169.12. The company has a market cap of $13.77 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.93 and a beta of 0.89. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.85 EPS. Equities research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on DVA. Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Truist Financial increased their price target on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a report on Monday, October 7th. Finally, Barclays upped their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $161.80.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the sale, the chief executive officer now owns 887,835 shares in the company, valued at approximately $144,583,929.75. This represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.00% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.